Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement
Argobio and GeneCode have announced their collaboration to develop small molecule Glial cell line - Derived Neurotrophic Factor (GDNF) mimetics for the treatment of Parkinson’s Disease and other indications.
In the venture studio model developed by Argobio, breakthrough technologies are embraced by a team of scientific experts with an entrepreneurial and industrial experience. Over the course of incubation, Argobio will fund the project development up to 3 ME and incorporate the start-up. After incubation, further venture funding will be provided by specialized VC investors.
“The launch of our first collaboration is a great achievement for Argobio. Argobio intends to incubate until series A at least five projects in the fields of rare diseases, neurosciences, and oncology over the next three years. With a committed capital of €50 million, and a team of pharma industry experts, Argobio expects to deliver strong projects, well-prepared for Series A funding,”Thierry Laugel Argobio Chairman said.
GeneCode, a discovery-stage biotech company developing small molecule GDNF mimetics, in collaboration with the laboratory of Mart Saarma, Professor and Research Director of the Institute of Biotechnology, HI-LIFE, University of Helsinki, Finland, has identified and patented a series of small molecules activating the GDNF signalling receptor RET tyrosine kinase. Professor Saarma´s team has discovered GDNF receptors, clarified the GDNF-receptor structure and investigated the therapeutic potential of GDNF family members.
Professor Mart Saarma commented,“Argobio’s investment and participation in the development of effective GDNF mimetics is extremely encouraging news. GDNF mimetics can overcome the limitations of the GDNF protein and can open up a completely new page in the treatment of Parkinson’s disease.”
GeneCode CEO Paavo Pilv added,“Our combined expertise will catapult this technology beyond what we would have been able to achieve alone. Considering the pivotal role of GDNF family ligands and RET signalling pathways for other groups of cells, applications of compounds developed by GeneCode are not limited only to Parkinson’s Disease but can be applied to treat other medical conditions.”
“We have ambitious goals for the next two years,”Argobio Entrepreneur in Residence Yves Ribeill, PhD said.“The whole is greater than the sum of the parts with the combined, diverse expertise of GeneCode, Argobio and Professor Saarma. I am confident that we will be able to demonstrate that the unique business model of funded partnerships initiated by Argobio in Europe will give new therapeutics a boost to succeed.”
About Argobio: www.argobiostudio.com
Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies. Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology, and immunology. Argobio selects and incubates these projects with the goal to create biotech companies and develop (or lead) them up to a significant Series A financing. Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio.
Follow us on LinkedIn.
About GeneCode: www.GeneCode.com
GeneCode is a private pharmaceutical development company focused on the development of disease-modifying therapeutics to combat neurodegeneration. The GDNF Mimetics platform leverages the disease-modifying properties of GDNF to small molecules with drug-like properties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005337/en/
Contact information
NewCap – Media relations:
Nicolas Merigeau – nmerigeau@newcap.fr – +33 1 44 71 94 98
Arthur Rouillé – arouille@newcap.fr – +33 1 44 71 00 15
Argobio:
Yves Ribeill – yves.ribeill@argobiostudio.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Long Tale Games Relaunches Life is Feudal: MMO on Steam With a Significant Event, the Balance Restoration Campaign18.4.2024 14:00:00 CEST | Press release
Long Tale Games (LTG) announces the Steam relaunch of Life is Feudal: MMO. To show appreciation to the game's community, the publisher is launching a special event aimed at the game's original players, the Balance Restoration Campaign. Players who have made any purchases during the previous Life is Feudal: MMO round will receive special LiF Coins that can be exchanged for a subscription to the game. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418169927/en/ (Graphic: Business Wire) Since the relaunch in June 2023, Life is Feudal: MMO has transitioned to a subscription-based model, removing all pay-to-win features. This shift ensures a level playing field for all players, fostering fairness as success in the game now fully depends on the player's skill and effort, creating a more engaging environment. Until now, the game has only been distributed through the publisher's (LTG.com) own personal gaming platform. However, wi
Newmont Publishes 2023 Sustainability Report and 2023 Tax & Royalties Report18.4.2024 14:00:00 CEST | Press release
Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today published its 2023 Sustainability Report and its 2023 Taxes and Royalties Contributions Report. The reports highlight the company’s material ESG and socio-economic contributions over the past year. This year marks the 20th anniversary for Newmont’s Annual Sustainability Report, representing a milestone for the company as a longstanding industry leader in sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417961090/en/ Newmont's 2023 Sustainability Report (Graphic: Business Wire) "Our 2023 Sustainability Report demonstrates our unwavering commitment to responsible resource management and the integral role that Newmont plays in creating a more sustainable future," said Newmont Chief Safety and Sustainability Officer Suzy Retallack. "We recognize the responsibility we have to mitigate our environmental impact and make a difference in the areas w
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain18.4.2024 14:00:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548). Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain. Vertex has started the rolling submission process and is on track to complete the submission in the second quarter of 2024. Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain. In neuropathic pain, Vertex released positive results from its Phase 2 study in December 2023 and recently completed a successful end-of-phase 2 meeting with the FDA. Vertex is now preparin
MediaCo Acquires Estrella Media’s Content and Digital Operations18.4.2024 13:36:00 CEST | Press release
MediaCo Holding Inc. (Nasdaq: MDIA) (“MediaCo”) today announced that it has acquired all of Estrella Media’s network, content, digital, and commercial operations. Among the Estrella Media brands joining MediaCo are the EstrellaTV network and its influential linear and digital video content business, and Estrella Media’s expansive digital channels, including its four FAST channels – EstrellaTV, Estrella News, Cine EstrellaTV, and Estrella Games – and the EstrellaTV app. The transaction closed on April 17, 2024. MediaCo, which operates marquee urban radio stations HOT 97 and WBLS 107.5 in New York City, will be adding Estrella Media’s Spanish-language video, audio, and digital content operations under the same umbrella. This transaction will also allow MediaCo to reach the established audiences of Estrella Media’s market-leading Regional Mexican radio stations, including Que Buena Los Angeles, home of the Don Cheto Al Aire nationally syndicated morning radio show, La Raza in Houston and
TriLink BioTechnologies ® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production18.4.2024 13:36:00 CEST | Press release
TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418722567/en/ TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®) Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom